YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Collaboration to Support Potential Commercialization of Intismeran Autogene CHICAGO, October 07, 2026--(BUSINESS WIRE)--Tempus (NASDAQ: TEM) today announced an expanded, multi-year collaboration to support the potential commercialization o…
The S&P 500 hit a high as the stock market extended a win streak. Astera Labs, GE Vernova and Arista Networks led AI stock buys. Continue Reading
The S&P 500 hit a high as the stock market extended a win streak. Astera Labs, GE Vernova and Arista Networks led AI stock buys. Continue Reading
BTIG on Tuesday downgraded Personalis (PSNL [https://seekingalpha.com/symbol/PSNL]) to Neutral from Buy, noting that Tempus AI (TEM [https://seekingalpha.com/symbol/TEM]), which has agreed to acquire the cancer test maker, will succeed in…
Cyera ranks No. 1 in the global ranking; annual list spotlights companies best positioned to deliver sustained, long-term growth U.S. companies dominate tech-heavy list, with 8 in the Top Ten, and 86 of the total Fortune Future 120 By regi…
Tempus AI (TEM) has moved back into focus after receiving 510(k) clearance from the U.S. Food and Drug Administration for Tempus ECG-MR, an AI tool for early mitral regurgitation detection. The FDA decision has landed on top of a strong ru…
Recent advancements in Artificial Intelligence (AI) have revolutionized the application of electrocardiography (ECG) in cardiovascular diagnostics. The AI-ECG analysis market size is expected to grow from $2.01 billion in 2025 to $2.40 bil…
Equity Insider News Commentary AUSTIN, Texas, Oct. 1, 2026 /PRNewswire/ -- Towards Healthcare projects that the global AI in drug discovery market will grow from $19.89 billion in 2025 to $160.49 billion by 2035, a compound annual growth r…
CHICAGO, October 01, 2026--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that 13 abstracts have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23–27 i…
CALGARY, AB, Sept. 29, 2026 /PRNewswire/ -- Providence Therapeutics Holdings, Inc. is pleased to announce formation of its initial Clinical Advisory Board. This advisory group will help steer Providence's therapeutic mRNA cancer vaccine pr…
ECG-MR becomes the fourth FDA-cleared Tempus ECG-AI product, spanning arrhythmia, heart function, pulmonary vascular and valvular disease CHICAGO, September 28, 2026--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced it has re…
Cathie Wood’s Ark Invest boosted its technology, biotechnology, and space exposure last week, led by purchases of more than 51K shares of Meta Platforms (META [https://seekingalpha.com/symbol/META]) worth $38.2M and roughly 360K shares of…
Rising demand for precision and personalized medicine has significantly augmented the need for artificial intelligence (AI)-enabled medical devices to deliver highly individualized diagnostics and treatments. Over the past several months,…
[AGREEMENT CONCEPT] cnythzl/iStock via Getty Images TempraMed Technologies (TMPTF [https://seekingalpha.com/symbol/TMPTF]) announced an amendment to its exclusive distribution agreement [https://seekingalpha.com/pr/20662495-tempramed-expan…
Goldman Sachs' Neutral initiation of Tempus AI, Inc. (NASDAQ:TEM) on September 21 puts the company's fastest-growing businesses under different tests: diagnostics offers visible near-term growth, while the data and applications segment fac…
CHICAGO, September 21, 2026--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced an extension of its data license agreement with Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX). Additionally, the two companies have entered into a…
On September 9, Tempus AI (NASDAQ:TEM) said ARPA-H, a US health research agency, picked it to build an AI that treats heart failure patients without a clinician stepping in. The award is worth up to $9.5 million, which is small change for…
Tempus AI (TEM) has put a new data project at the center of the story. The business plans a research platform built on 100,000 whole genomes linked to long term clinical records. Tempus AI's new whole genome project arrives after a sharp r…
Earlier this month, Tempus AI announced a multi‑year initiative to build a research platform of 100,000 whole genomes linked to longitudinal clinical, imaging, pathology and outcome data, with plans to eventually scale toward one million g…
Tempus AI (NasdaqGS:TEM) announced a new whole-genome sequencing initiative linked to clinical data for AI research in September 2026. The project aims to create a de-identified multimodal dataset that connects full genome reads with real-…
Tempus AI TEM shares rallied 14.9% in the last trading session to close at $80.36. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 14.2% ga…
For Immediate Release Chicago, IL – September 18, 2026 – Today, Zacks Investment Ideas features NVIDIA NVDA, Advanced Micro Devices AMD, Tempus AI TEM, Moderna MRNA, Super Micro Computer SMCI and Aya Gold & Silver Inc (AYA). Will 2026 Doom…
Caris Life Sciences Stock Jumped 10% Yesterday. Here's Where Shares Could Go Further in 2026. ©TIKR Key Takeaways Sector Rally: Caris Life Sciences (CAI) stock jumped 9.61% to close at $31 on Thursday, September 17, riding a Fed-driven mar…
2026 Has Been Full of Uncertainty So far in 2026, Wall Street equity investors have navigated an extremely complex landscape marked by macroeconomic forces, geopolitical pressures, and sector-specific concerns. Inflation has remained stubb…
Clarity on how much revenue Tempus AI will bring in through Medicare reimbursements for two of its cancer screenings appeased investors this week as shares surged Thursday. Tempus stock added 15% Thursday as part of a 36% advance over the…
Quick Read TEM surged 30% this week after Morgan Stanley spotlighted reimbursement pricing that could add between $330M and $400M in combined annual revenue across xT and xF diagnostics. Lefkofsky says Tempus will exceed its 25% multiyear…
Neuraxis, Inc.'s NRXS investors have been gaining from the stock over the past year. Shares of the Carmel, IN-based medical technology company gained 136.6% in the past year against the industry's 12.2% decline. It has also outperformed th…
This article first appeared on GuruFocus. Cathie Wood's Ark Invest made a sharp rotation across technology and biotechnology stocks last week, buying roughly $28 million of Meta Platforms (NASDAQ:META) while selling a nearly identical doll…
Cathie Wood, head of Ark Investment Management, often buys her favorite tech stocks when she sees a new opportunity. That's what she did last week, pouring $27.9 million into Meta Platforms (META) as the company pushes deeper into AI. Last…
[Interest rate percentage sign symbol finance investment graph chart] alexsl The Goldman Sachs equity team has rebalanced its Long Duration Basket amid rising interest rates. Equities usually struggle to digest sharp increases in interest…
The Initiative Will Make Available 100,000 Disease-Specific Whole Genome Sequences Paired with Longitudinal Clinical Outcomes, with a Long-Term Goal of Reaching 1 Million Genomes CHICAGO, September 11, 2026--(BUSINESS WIRE)--Tempus AI, Inc…
Cathie Wood, chief of Ark Investment Management, likes to chase momentum in her favorite tech bets. This week, she's buying $6.5 million of Cerebras stock as the AI chip stock surges. Last year, the flagship Ark Innovation ETF gained 35.49…
The Initiative Will Pioneer an AI Agent That Functions as an Extension of the Clinician Team, Capable of Delivering and Coordinating Cardiovascular Care Without Direct Human Intervention CHICAGO, September 09, 2026--(BUSINESS WIRE)--Tempus…
Cathie Wood's firm ARK Invest added to its already sizable position in the trading platform Robinhood, which is back in a buy zone. Continue Reading
[FDA Headquarters] The Trump administration on Tuesday appointed the acting heads of the FDA units overseeing drugs, vaccines, and tobacco to permanent positions weeks after nominating White House advisor Heidi Overton as the agency's next…
[Bitcoin 2022 Conference Draws Cryptocurrency Industry Professionals And Investors To Miami] Marco Bello/Getty Images News Cathie Wood’s Ark Invest leaned further into high-growth themes, including space, fintech, crypto, and biotechnology…